Autologous T-Cell Therapy Promising in Advanced Sarcoma – Oncology Nurse Advisor


Oncology Nurse Advisor
Autologous T-Cell Therapy Promising in Advanced Sarcoma
Oncology Nurse Advisor
CHICAGO Infusion of autologous HER2-CAR T cells after lymphodepletion is safe and appears to be associated with objective clinical benefit in patients with advanced HER2+ sarcoma, according to the findings of a small phase I study presented at the ...

Go here to see the original:
Autologous T-Cell Therapy Promising in Advanced Sarcoma - Oncology Nurse Advisor

Cell Therapy for Stress Urinary Incontinence: Present-Day Frontiers. – UroToday

Stress urinary incontinence (SUI) significantly diminishes the quality of patients' lives. Currently available surgical and nonsurgical therapies remain far from ideal. At present advancements in cellular technologies have stirred growing interest in the use of autologous cell treatments aimed to regain urinary control.

To conduct a review of the literature and analyze preclinical and clinical studies dedicated to various cell therapies for SUI, assessing their effectiveness, safety, and future prospects.

A systematic literature search in PubMed was conducted using the following key terms: "stem," "cell," "stress," "urinary," and "incontinence." A total of 32 preclinical studies and 15 clinical studies published between 1946 and December 2014 were included in the review.

Most preclinical trials have used muscle-derived stem cells (MDSCs) and adipose-derived stem cells (ADSCs). Yet, at present, the application of other types of cells, such as human amniotic fluid stem muscle-derived progenitor cells (hAFSCs), and bone marrow mesenchymal stromal cells (BMSCs), is becoming more extensive. While the evidence shows that these therapies are effective and safe, further work is required to standardize surgical techniques, as well as to identify indications for their use, doses and number of doses.

Future research will have to focus on clinical applications of cell therapies; namely, it will have to determine indications for their use, doses of cells, optimal surgical techniques and methods, attractive cell sources, as well as to develop clinically relevant animal models and make inroads into understanding the mechanisms of SUI improvement by cell therapies.

Journal of tissue engineering and regenerative medicine. 2017 May 08 [Epub ahead of print]

Andrey Vinarov, Anthony Atala, James Yoo, Roman Slusarenco, Marat Zhumataev, Alexey Zhito, Denis Butnaru

Research Institute for Uronephrology and Reproductive Health, Sechenov First Moscow State Medical University, Moscow, Russian Federation., Wake Forest School of Medicine, Winston-Salem, NC, USA., Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA., Sechenov First Moscow State Medical University, Moscow, Russian Federation., Institute for Regenerative Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/28482121

Read more:
Cell Therapy for Stress Urinary Incontinence: Present-Day Frontiers. - UroToday

Custom Stem Cell Treatment Now Available for Orthopedic Pain – PR Web (press release)

NextStem logo

Tampa, FL (PRWEB) June 05, 2017

NextStem, a premier stem cell therapy service, is now offering a breakthrough treatment for pain management related to musculoskeletal injuries and joint conditions.

"Patients experiencing painful joints related to sports injuries, arthritis and other ailments now have an alternative treatment to surgery, says NextStem founder Rodolfo Gari, M.D., M.B.A. Its a new and better option for reclaiming a pain-free life.

Stem cell therapy is a process that uses unspecified cells to renew themselves and in some cases be turned into cells with specialized functions. Individual doctors partnering with NextStem have been using stem cell therapy since 2008, two years after researchers discovered that specialized adult cells could be genetically reprogrammed to assume a stem cell-like state.

Advantages of NextStem therapy are many:

Stem cell therapy may also involve injecting stem cells or blood products, known as plasma rich platelets, to relieve joint and muscle pain caused by injury, chronic conditions even previous surgeries. PRP treatments have been used by more than 70 professional athletes to relieve pain.

NextStem, based in Tampa, Fla., is currently available to patients in two locations in Texas and Florida, with plans to expand. In Texas, it is available at the Hurst Ambulatory Surgery Center, 1717 Precinct Line Road, Suite 101, (817) 605-9899; and in the Tampa Ambulatory Surgery Center, 4726 N. Habana Ave., Suite 100, (813) 769-8855.

For more information, call 855-957-3436 or visit http://www.nextstem.com

Share article on social media or email:

Link:
Custom Stem Cell Treatment Now Available for Orthopedic Pain - PR Web (press release)

Embryonic stem cell trials to launch in China – BioEdge

China will begin trialling the use of embryonic stem-cells (ES) to treat Parkinsons disease and macular degeneration, in a move that has met with criticism from international experts.

The trials, which come in the wake of new stem-cell regulations introduced in China in 2015, will test the efficacy of injecting ES-derived cells into damaged areas of the brain and eyes.

In one trial, ES-derived neuronal-precursor cells will be injected into the areas of the brain affected by Parkinsons disease in attempt to regenerate dopamine-producing tissue. In another trial, the ES-derived retinal cells will be injected into eyes of people with age related macular degeneration. It is believed that the retinal cells may be able to replace cells damaged as a result of epithelial tissue degeneration.

It will be a major new direction for China, Pei Xuetao, a stem-cell scientist at the Beijing Institute of Transfusion Medicine who is on the central-government committee that approved the trials, told Nature.

Other researchers who work on Parkinsons disease, however, worry that the trials might be misguided.

Jeanne Loring, a stem-cell biologist at the Scripps Research Institute in La Jolla, California, who is also planning stem-cell trials for Parkinsons, is concerned that the Chinese trials use neural precursors and not ES-cell-derived cells that have fully committed to becoming dopamine-producing cells. Precursor cells can turn into other kinds of neurons, and could accumulate dangerous mutations during their many divisions, says Loring. Not knowing what the cells will become is troubling.

Lorenz Studer, a stem-cell biologist at the Memorial Sloan Kettering Cancer Center in New York City, says that support is not very strong for the use of precursor cells. I am somewhat surprised and concerned, as I have not seen any peer-reviewed preclinical data on this approach, he told Nature.

See the original post here:
Embryonic stem cell trials to launch in China - BioEdge

Cancer Gene Therapy and Cell Therapy | ASGCT – American …

Cancer is an abnormal growth of cells the proximate cause of which is an imbalance in cell proliferation and death breaking-through the normal physiological checks and balances system and the ultimate cause of which are one or more of a variety of gene alterations. These alterations can be structural, e.g., mutations, insertions, deletions, amplifications, fusions and translocations, or functional (heritable changes without changes in nucleotide sequence). No single genomic change is found in all cancers and multiple changes (heterogeneity) are commonly found in each cancer generally independent of histology. In healthy adults, the immune system may recognize and kill the cancer cells or allow a non-detrimental host-cancer equilibrium; unfortunately, cancer cells can sometimes escape the immune system resulting in expansion and spread of these cancer cells leading to serious life threatening disease. Approaches to cancer gene therapy include three main strategies: the insertion of a normal gene into cancer cells to replace a mutated (or otherwise altered) gene, genetic modification to silence a mutated gene, and genetic approaches to directly kill the cancer cells.

Furthermore, approaches to cellular cancer therapy currently largely involve the infusion of immune cells designed to either (i) replace most of the patients own immune system to enhance the immune response to cancer cells, (ii) activate the patients own immune system (T cells or Natural Killer cells) to kill cancer cells, or (iii) to directly find and kill the cancer cells. Moreover, genetic approaches to modify cellular activity further alter endogenous immune responsiveness against cancer.

Currently, multiple promising clinical trials using these gene and cell based approaches are ongoing in Phase I through Phase III testing in patients with a variety of different types of cancer.

Cancer is a process in which cells grow aberrantly. The growth of cancer cells leads to damage of normal tissues, causing loss of function and often pain. Many types of tumors shed cells that migrate to other distant sites in the body, establish a base there, and grow continuously. These secondary cancer sites, called metastases, cause local destruction, loss of normal tissue function and can acquire an even greater propensity to shed. Multiple cumulative genetic and/or epigenetic changes are needed to cause cancer. Those genes on which the maintenance of the cancer process depends are called driver genes which, unlike passenger genes, are key targets although non-driver genes can also contribute to cancer growth.

A number of gene therapy strategies are being evaluated in patients with cancer and these include manipulating cells to gain or lose function. For example, half of all cancers have a mutated p53 protein that interferes with the ability of tumor cells to self-destruct by a process called apoptosis. To this end, investigators are currently testing in clinical trials the ability to genetically introduce a normal p53 gene into these cancer cells. Introduction of a normal p53 gene renders the tumor cells more sensitive to standard chemotherapy and radiation treatments compared to tumor cells expressing the abnormal protein. Furthermore, other tumor suppressor genes are being placed in gene cassettes for expression in tumor cells, which can similarly render them more sensitive to apoptosis, or the process of programmed cell death. Other investigators are utilizing gene therapy approaches to induce expression of immune stimulating proteins called cytokines which in turn may increase the ability of the patients own immune system to recognize and kill these cancer cells. Another immune modulating alternative entering the clinic is the use of RNA interference (RNAi) silencing of endogenous cancer intracellular immune suppressor proteins, e.g., TGF beta, as a component of immunotherapy.

Along this line, gene silencing has been designed to inhibit the expression of specific genes which are activated or over expressed in cancer cells and can drive tumor growth (with particular attention to presumptive driver genes), blood vessel formation, seeding of tumor cells to other tissues, and allow for resistance to chemotherapy. Several such genes, termed oncogenes, are often expressed continuously at high concentrations in cancer cells and express proteins that increase cell growth and/or division. Alternatively, tumor growth requires new blood vessel formation to survive, a process known as angiogenesis, which is mediated by an array of interacting proteins. A number of approaches to gene silencing have been or are being explored in the clinic including anti-sense oligonucleotides (ASO), short interfering RNA (siRNA) and short hairpin RNA (shRNA) that target post-transcription mRNA, and bi-functional shRNA which has both post-transcriptional silencing and translation-inhibitory effects.

Furthermore, tumor cells can loose intercellular cohesion, enter the bloodstream and seed other tissues, enabled by epithelial-mesenchymal transition, where they can undergo mesenchymal-epithelial transition and grow at the newly seeded site; once again mediated by a different set of genes. Finally, scientists have identified genes in tumor cells, which allow for these tumor cells to escape killing by chemotherapy. Therefore, an alternative gene therapy approach for cancer is to target one or more of these genes in order to suppress or silence their expression resulting in an inability of these tumor cells to either maintain cell growth, inhibit metastases, impair blood vessel formation, or reverse drug resistance. Mesenchymal stem cells, which have cancer-trophic migratory properties, are being engineered to express anti-proliferative, anti-EMT, and anti-angiogenic agents.

Alternatively, gene therapy approaches may be designed to directly kill tumor cells using tumor-killing viruses, or through the introduction of genes termed suicide genes into the tumor cells. Scientists have generated viruses, termed oncolytic viruses, which grow selectively in tumor cells as compared to normal cells. For example, an expanding number of human viruses such as measles virus, vesticular stomatitis virus, reovirus, adenovirus, and herpes simplex virus (HSV) can be genetically modified to grow in tumor cells with consequent cell kill, but very poorly in normal cells thereby establishing a therapeutic advantage. . Oncolytic viruses spread deep into tumors to deliver a genetic payload that destroys cancerous cells. Several viruses with oncolytic properties are naturally occurring animal viruses (Newcastle Disease Virus) or are based on an animal virus such as vaccinia virus (cow pox virus or the small pox vaccine). A few human viruses such as coxsackie virus A21 are similarly being tested for these properties. In addition, oncolytic viruses can be genetically modified (i.e. GM-CSF DNA transfer)so as to enhance immunogenicity (e.g., HSV). The combination of selective oncolytic cell death with release of danger-associated molecular-patterns and tumor-associated antigens with heightened immunogenicity has been shown both enhanced local and spatially additive effects. Currently, multiple clinical trials are recruiting patients to test oncolytic viruses for the treatment of various types of cancers.

Suicide genes encode enzymes that are produced in tumor cells to convert a nontoxic prodrug into a toxic drug. Examples of suicide enzymes and their prodrugs include HSV thymidine kinase (ganciclovir), Escherichia coli purine nucleoside phosphorylase (fludarabine phosphate), cytosine deaminase (5-fluorocytosine), cytochrome p450 (cyclophosphamide), cytochrome p450 reductase (tirapazamine), carboxypeptidase (CMDA), and a fusion protein with cytosine deaminase linked to mutant thymidine kinase. Significantly, prior pilot studies suggested that the treatment of the prostate cancer cells with the suicide genes introduced by the oncolytic virus increased cancer cell sensitivity to radiation and chemotherapy.

Most of the above approaches have the limitation that they require delivery of a "corrective" gene to every cancer cell, a demanding task. An alternative is to harness the immune system, which may have an ability to actively seek out cancer cells. In healthy adults, the immune system recognizes and kills precancerous cells as well early cancer cells, but cancer progression is an evolutionary process and results in large part from an immune-evasive adaptive response to the cancer microenvironment affecting both the afferent and efferent arms of the immune response arc. This results in inhibition of the ability of a patients immune system to target and eradicate the tumor cells. To this end, investigators are developing and testing several cell therapy strategies to correct impairment of the host-cancer immune interaction and as a consequence, to improve the immune systems ability to eliminate cancer.

Cell therapy for cancer refers to one or more of 3 different approaches: (i) therapy with cells that give rise to a new immune system which may be better able to recognize and kill tumor cells through the infusion of hematopoietic stem cells derived from either umbilical cord blood, peripheral blood, or bone marrow cells, (ii) therapy with immune cells such as dendritic cells which are designed to activate the patients own resident immune cells (e.g. T cells) to kill tumor cells, and (iii) direct infusion of immune cells such as T cells and NK cells which are prepared to find, recognize, and kill cancer cells directly. In all three cases, therapeutic cells are harvested and prepared in the laboratory prior to infusion into the patient. Immune cells including dendritic cells, T cells, and NK cells, can be selected for desired properties and grown to high numbers in the laboratory prior to infusion. Challenges with these cellular therapies include the ability of investigators to generate sufficient function and number of cells for therapy.

Clinical trials of cell therapy for many different cancers are currently ongoing. More recently, scientists have developed novel cancer therapies by combining both gene and cell therapies. Specifically, investigators have developed genes which encode for artificial receptors, which, when expressed by immune cells, allow these cells to specifically recognize cancer cells thereby increasing the ability of these gene modified immune cells to kill cancer cells in the patient. One example of this approach, which is currently being studied at multiple centers, is the gene transfer of a class of novel artificial receptors called chimeric antigen receptors or CARs for short, into a patients own immune cells, typically T cells. Investigators believe that this approach may hold promise in the future for patients many different types of cancer. To this end, multiple pilot clinical trials for a variety of cancer types using T cells genetically modified to express tumor specific CARs are ongoing, some of which are showing promising results.

See the original post:
Cancer Gene Therapy and Cell Therapy | ASGCT - American ...

Mother considers adult stem cell treatment for son – The Lawton Constitution


The Lawton Constitution
Mother considers adult stem cell treatment for son
The Lawton Constitution
APACHE Pamela Nation hopes a new experimental treatment can help her 10-year-old son live a healthier and more independent life. Shane Parrott is a third-grader at Elgin Elementary School. While other kids are learning their multiplication tables ...

Go here to read the rest:
Mother considers adult stem cell treatment for son - The Lawton Constitution

Sioux Falls Man Received Treatment Using His Own Fat Stem Cells – KDLT News (blog)

SIOUX FALLS, S.D. Doctors say a breakthrough in stem cell research from over a decade ago could someday replace traditional medicine. A procedure using a patients own fat stem cells has already helped many people across the world, but these types of procedures havent been approved in the U.S. Thats why one Sioux Falls man and some Sanford doctors traveled to Munich, Germany last year.

Imagine a more natural way of treating pain or even a more advanced treatment for cancer. What if I told you common ailments like chronic back pain or arthritis could be healed? Thats what doctors say treatments using a patients own stem cells could do. One of those doctors is German Doctor Eckhard Alt.

The next generation of medicine would be to learn how we can heal ourselves, without artificial implants, without drugs, that we use the regenerative power of our own body, said Dr. Alt.

This might sound like something out of a Sci-Fi movie, but Dr. Alt says this type of practice is already being brought to clinical practice.

In nature, tells you there is a regenerative potential in all of us. If you look at the lizard, you cut off the tail, it even has the ability to re-grow, said Dr. Alt

Doctors say many patients have chronic pain and have exhausted all of their options. Thats what happened to one Sioux Falls man, Bill Marlette. He lost one of his arms in an accident when he was a teenager, resulting in more stress on his other wrist. Marlette said the excessive stress on his wrist caused a lot of pain, even when doing everyday activities. When his doctor heard about Dr. Alts practices, he suggested the procedure using his own fat stem cells. Last year, Marlette traveled to Munich, Germany with some Sanford Doctors to repair his wrist.

Its made my life more active and pain free again, said Sanford Health Treasurer, Bill Marlette.

Marlette said he hopes the national exposure from his story can help Sanfords goal of bringing treatments like this to the region. He said the procedure has been life changing for him and could benefit many other patients.

Without this I, I would be probably really scaling back in what I could do, said Marlette.

Marlette said 2 weeks after the procedure pain had already started to go away. Now, 7 months later he said hes pain free.

Read the original post:
Sioux Falls Man Received Treatment Using His Own Fat Stem Cells - KDLT News (blog)

Researchers will attempt to ‘reanimate’ a corpse with stem cells – Engadget

"It's our contention that there's no single magic bullet for this, so to start with a single magic bullet makes no sense. Hence why we have to take a different approach," Bioquark CEO, Ira Pastor, told Stat News.

As Pastor told the Washington Post last year, he doesn't believe that brain death is necessarily a permanent condition, at least to start. It may well be curable, he argued, if the patient is administered the right combination of stimuli, ranging from stem cells to magnetic fields.

The resuscitation process will not be a quick one, however. First, the newly dead person must receive an injection of stem cells derived from their own blood. Then doctors will inject a proprietary peptide blend called BQ-A into the patient's spinal column. This serum is supposed to help regrow neurons that had been damaged upon death. Finally, the patient undergoes 15 days of electrical nerve stimulation and transcranial laser therapy to instigate new neuron formation. During the trial, researchers will rely on EEG scans to monitor the patients for brain activity.

This isn't the first time that Bioquark has attempted this study. Last April, the company launched a nearly identical study in Rudrapur, India. However, no patients enrolled and the study wound up getting shut down that November by the Indian government over clearance issues with India's Drug Controller General. Bioquark is reportedly nearing a deal with an unnamed Latin American country to hold a new trial later this year.

Whether the treatment will actually work is an entirely different matter. Bioquark admits that it has never actually tested the regimen, even in animals, and the various component treatments have never themselves been applied to brain death. They've shown some promise in similar cases like stroke, brain damage and comas but never actually Lazarus-ing a corpse.

"I think [someone reviving] would technically be a miracle," Dr. Charles Cox, a pediatric surgeon at the University of Texas Health Science Center at Houston, told Stat News. "I think the pope would technically call that a miracle."

Read the rest here:
Researchers will attempt to 'reanimate' a corpse with stem cells - Engadget

Researchers Deplete Cancer Stem Cells to Fight Recurring Brain Tumors – SelectScience

Brain cancer researcher, Dr. Raffaella Spina, explains cancer recurrence in glioblastomas and her approaches to fight it in the laboratory

H&E staining of a brain section showing invasive and proliferative tumors. Image courtesy of Dr. R Spina

Dr. Spina is a brain cancer researcher at the Case Reserve Western University School of Medicine. After completing her Ph.D. in Molecular Oncology and Experimental Immunology, her primary focus for the past nine years has been the cellular and molecular biology of pediatric and adult brain tumors. As a postdoctoral researcher in the laboratory of Dr. Eli E. Bar, she studies cellular heterogeneity in tumors and tumor microenvironment.

The glioblastomas are the most stubborn and aggressive of brain cancers. Referred to as glioblastoma multiforme, this form of grade IV brain tumor is considered malignant. Once diagnosed, doctors surgically remove the tumor from the brain, and prescribe concurrent radiation and oral chemotherapy for the weeks that follow.

Even with these efforts, the cancer returns. With no definite cure, patients tend to succumb to glioblastomas in about one year.

Dr. Raffaella Spina, a cancer researcher at the Case Western Reserve University, studies glioblastomas. In this interview with SelectScience, she explains the source of cancer recurrence and her recent efforts to tackle glioblastoma in a lab.

Cancer stem cells: the source of tumor recurrence

The resistance to current therapies and tumor recurrence in cancer can be attributed to a source cancer stem cells. In glioblastoma, these cells are called glioblastoma stem cells (GSCs) and this is the focus of Dr. Spinas research.

The GSCs, possessing properties of stem cells, have the capacity to produce progeny cells, some of them cancerous. Surgical removal of the tumor may not clear the GSCs, causing future recurrence of the cancer. Dr. Spina and her academic advisor, Dr. Eli E. Bar, have one goal: finding a way to wipe out these cancer stem cells.

Approach 1. Controlling the progenies of cancer stem cells

While many laboratories examine the properties of the GSCs themselves, Dr. Spina and her colleagues took a different approach to study the progenies of the cancer stem cells.

Forcing the cancer stem cells to differentiate into non-cancerous progeny cells can deplete the GSC pool without the risk of cancer recurrence. One approach our group has been studying for the past several years is aimed at promoting the astroglial differentiation, says Dr. Spina. She studied the progenies of the GSCs, i.e. astrocytes and neurons, and identified them using specific reporters glial fibrillary acidic protein (GFAP) for astrocytic differentiation, and microtubule-associated protein-2 (MAP-2) for neuronal differentiation. When the GSCs differentiated to astroglial-like cells (GFAP-positive), these progenies showed reduced tumorigenic capacities, both in vitro and in vivo. These benefits, however, werent observed with the neuronal (MAP-2 positive) progenies.

Molecules that can control cancer stem cells fate

In the next step, a drug screening ensued to identify different small molecules that can differentiate cancer stem cell pools into solely astroglial progenies. A neuromuscular blocker, atracurium besylate, emerged as the top candidate as it induced the GSCs into only astroglia and not neurons. Our most clinically relevant results show that astrocytic differentiation, induced by Atracurium Besylate, is associated with reduced GSC self-renewal in vitro, and reduced the capacity to initiate cancer in orthotopic xenografts in vivo, summarizes Dr. Spina. We propose that targeting cancer stem cells with therapies that induce their differentiation can reduce the fraction of cancer stem cells capable of brain tumor initiation, and thereby, inhibit tumor progression.

A high-throughput screening platform

To monitor the astroglial differentiation (i.e. GFAP-positive progenies) during the small-molecule screen, Dr. Spina performed flow cytometry using MilliporeSigma'sbenchtop flow cytometer. In our latest publication, Spina et al., Oncotarget, 2016[1], the Guava 5HT flow cytometer allowed us to establish a high-throughput screening platform. This helped us identify small molecules capable of inducing astroglial differentiation of GSCs, based on GFP expression driven by the promoter of human GFAP, adds Dr. Spina. It is a reliable, accurate and user-friendly flow cytometer with a very intuitive software and an essential instrument in our lab, she acknowledges. The new molecular targets identified in this project, including atracurium besylate, will be further studied to develop future therapeutic strategies to eradicate GSCs.

The new-found link between cancer stem cells and acetylcholine signaling

Atracurium besylate, the small molecule that induces the GSCs to assume an astroglial-only fate, also happens to act as a specific inhibitor of nicotinic acetylcholine receptors (nAChR). Dr. Spinas findings have now provided an unexplored direct link between acetylcholine signaling and maintenance of stemness in cancer stem cells. Acetylcholine signaling has never before been implicated in glioma stem cell biology. We were the first laboratory to identify this crucial link, notes Dr. Spina. We hope that our paper[1] will prompt other laboratories and perhaps pharmaceutical companies to focus on identification of other inhibitors of acetylcholine signaling or downstream targets.

Approach 2. Making it difficult for cancer stem cells to survive

Another approach to tackle GSCs is to simply make it hard for the cancer stem cells to survive. Thriving in a hypoxic microenvironment, the GSCs rely on the monocarboxylate transporter-4 (MCT4) for their survival[2]. In glioblastoma patients, overexpression of MCT4 was linked with increased rate of the patients succumbing to cancer. Recently, Dr. Spina and the team screened molecules capable of inhibiting MCT4, thereby starving the GSCs. In a recent publication in Scientific Reports[3] (in press), Dr. Spina identified a compound acriflavine that obstructed the functioning of MCT-4 by inhibiting its interaction with a closely-associated chaperon.

Tackling stubborn, chemotherapy-resistant tumors

A tremendous effort in unveiling the molecular basis of chemo- and radiation-resistance is currently being made by the scientific community. A major challenge in decoding mechanisms of resistance is posed by intra-tumoral heterogeneity and cancer stem cells plasticity, reasons Dr. Spina, who was drawn to disease etiology, and the concept of research and experimentation as a college student. I chose to become a researcher because I have always been interested in understanding how our body works and how this information can be useful in fighting or avoiding illness.

Doing research is always fascinating, but at the same time challenging because biology can be very unpredictable, notes Dr. Spina. However, it is in these instances where I know novel discoveries can be made. This exciting aspect to research is what nourishes my passion to continue my scientific pursuits and provides me the hope that my efforts will contribute to the development of novel therapies, she adds. Dr. Spina plans to continue an in-depth analysis of the compounds identified in the small-molecule screening of both projects.

References:

Find out more aboutthe Guava 5HT Flow Cytometer and other MilliporeSigma instruments.

Do you useMilliporeSigma instruments in your research?Write a reviewtodayfor your chance to win an Amazon voucher worth $400 or an iPad.

Read more here:
Researchers Deplete Cancer Stem Cells to Fight Recurring Brain Tumors - SelectScience

First adult cured of sickle cell at a Kansas hospital – Washington Times

KANSAS CITY, Kan. (AP) - Intense pain. Fatigue. Repeated infections, emergency room visits and hospitalizations.

Desiree Ramirez endured them often - until she became the first adult cured at a Kansas hospital of sickle cell disease.

Bone marrow stem cells donated by a stranger rescued Ramirez at age 23. Now, a year past transplant, with follow-up doctors office visits slowly receding, she finds herself eagerly anticipating a normal life, one without the inherited blood disorder that affects 70,000 to 100,000 Americans, mostly people of African heritage.

I am doing a lot better now, Ramirez said during a recent checkup at the University of Kansas Cancer Center in Westwood. And I see better things to come in the future.

The Kansas City Star (http://bit.ly/2qBkGES ) reports that sickle cell disease deforms blood cells, causing them to clump together as they journey through the body. It can cause anemia, pain, strokes, organ damage, tissue damage, swelling of extremities and other health problems. The disease occurs in about one in 500 African-American newborns and one in 36,000 Hispanic-American newborns.

Though pioneered three decades ago as the first sickle cell cure, bone marrow stem cell transplants remain underused - especially for adult patients - because of the risks involved, a lack of public awareness and a shortage of bone marrow donors for African-Americans.

Nationwide, fewer than 120 such transplants took place last year. Childrens Mercy Hospital, which currently has about 300 sickle cell patients, has done four or five transplants over a 14-year period. The University of Kansas Hospitals transplant on Ramirez was the metro areas first on an adult with sickle cell.

In even smaller numbers, U.S. doctors also are using stem cells from peripheral blood and umbilical cord blood to cure patients. International researchers recently announced the first cure from gene therapy, which they used on a French teenager.

More public education about the cure and better recruitment of bone marrow donors could help more high-risk patients shed the disease, said Joseph McGuirk, medical director for blood and marrow transplant for the University of Kansas Health System.

This is an increasingly utilized strategy to cure patients - and cure is correct, he said, in reference to the fact that many still arent aware a cure exists.

Even the chief of staff once questioned McGuirk about whether he was going around telling people there was a cure. Actually, I am, answered McGuirk, who offered to send over some literature.

The news also stunned some African-American community leaders when McGuirk told them last year that sickle cell could be cured.

Many of them have begun spreading the word, too, by distributing brochures and discussing transplants at community health forums and other events.

Sickle cell is a really harsh disease to live with, said Eric Kirkwood, a sickle cell patient and the director of Uriel E. Owens Sickle Cell Disease Association of the Midwest. A lot of people could be cured with this transplant.

Yet its not an easy cure. And its not for everyone.

Some patients respond well to medication and can live with non-severe sickle cell symptoms for decades. They should not risk a transplant, which could leave them sicker - or even kill them, doctors say.

For those battling what McGuirk calls high-risk features of the disease, the transplants can prolong and transform lives. But if doctors wait too long, and the disease progresses too far, the patients transplant mortality chances grow too high.

The key is to strike a balance between too early and too late.

There are so many variables; it is not an easy decision, said Gerald Woods, Children Mercys director of hematology, oncology and bone marrow transplantation.

KU Hospital staff looked several years for their first patient. Weve seen a few referrals over the years, but when we have conferences with patients and their families, there is a lot of skepticism, McGuirk said.

Ramirez researched the procedure, peppered doctors with questions and discussed the possibilities with family. When she weighed the risks against how severely the disease had impacted her life, her decision came easily.

She didnt want to keep living the way she had been.

As an infant, Desiree Ramirez cried so hard her mother knew something was wrong.

I think all moms know the different cries their baby does, like a hunger cry versus this cry, said her mother, Lasherrez Clark of Topeka. This cry, it sounded like a pain cry. . I would take her in (to the doctor), and they couldnt figure out what was wrong.

When Ramirez was 3, her Topeka doctor finally ran blood tests. He sent Clark and her daughter to the University of Kansas Hospital to hear the results and talk treatment.

Both parents must have the gene for a baby to inherit the disease. Clark, who is African-American, had no idea she carried the sickle cell gene. Ramirezs father, who is Hispanic, didnt realize he carried it, either.

As Ramirez grew, her health problems multiplied. Pneumonia badgered her. Pain crises intensified and appeared more frequently. She needed amoxicillin to defeat repeated infections.

Clark rarely slept more than a few hours at a time. She had to look in on her daughter, check her temperature and listen for moaning. If a pain episode might be brewing, Clark wanted to get ahead of it with medication and hydration.

It is just such a debilitating disease and its so painful, and its hard to watch your child crying and screaming and theres nothing you can do about that, she said.

But sometimes, symptoms exploded suddenly.

Theyd go to an urgent care clinic only to be turned away because the clinic didnt treat sickle cell. Sometimes, hospital emergency room nurses acted skeptical, as if they thought this child had a pain medicine habit instead of actual pain.

Ramirez spent some birthdays and Christmases in the hospital. She found it difficult to make plans with friends because at the last minute, I might have to pull out because I am having a sickle cell crisis, and people dont understand that, she said.

One time, her mom splurged on concert tickets. At the last minute, sickle cell forced Ramirez to miss the concert.

Another time, they drove to Denver to start a family vacation, and Ramirez got sick as they arrived. Mom turned the car around and headed back to Topeka.

Its just really hard, Ramirez said. You can get infections at any moment. Its just a lot of complications.

About five years ago, they began investigating transplants. A move to Texas and other factors sidetracked those efforts. At one point, Ramirez enrolled in an Oklahoma college, later dropping out because of her disease.

After returning to Topeka, Ramirez and her mother reached out again to KU Hospital.

Soon, the search began for a bone marrow match.

Finding one can be a challenge. Perhaps 30 percent of all patients who need a bone marrow transplant will have a sibling who is a match. Others must turn to the worldwide donor registry. The news there for African-Americans, and other minorities, isnt always good.

A study released last year involving acute leukemia patients found that African-Americans chances of finding a match were half that of white patients, McGuirk said.

If a match is found, it still can take weeks to confirm the match and work out transplant details, assuming the donor doesnt back out.

Ramirez feels fortunate that the registry found multiple matches for her. A still-anonymous woman agreed to go through with the donation.

When she heard the news, Ramirez felt relieved. Her mother burst into tears.

Bone marrow transplants are complex.

Doctors use chemotherapy, and sometimes radiation, to eradicate the patients immune system.

About a week later, the bone marrow stem cell transplant takes place through a process that resembles a blood transfusion. The bone marrow flows from a bag into the patients vein as a nurse monitors the patients vitals for negative reactions.

The new immune system may not like its new host. It could recognize the patients body as foreign and attack everything from the skin to the liver and intestines in what is known as graft-versus-host disease. Such reactions can be mild, severe - or even fatal.

If treatment goes well, the patient typically stays in the transplant unit about three more weeks.

After being released, the patient must live within a 30-minute drive of the hospital for the next 100 days, which are filled with medical appointments. Later, the time between doctors appointments and lab tests gradually extends. Meanwhile, the patient stays on immunosuppressant drugs for months.

Ramirez, who grew to dislike hospitals as a child, took her own pillows, sheets, comforter, nightgowns, family photographs, slow cooker and coffee machine to the bone marrow transplant wing. It felt like setting up a dorm room, albeit one in a highly regulated, germ-free zone. The home comforts helped her cope, she said.

On transplant day, her mother and sister stayed with her. The transfusion took about 90 minutes.

A few days later, her hair came out in big chunks.

Her new immune system took hold. Her blood type became the same as her donors. Today, those blood cells still are normal, not shaped like a sickle, as her old blood cells were.

Though Ramirez did develop graft-versus-host disease, it was not severe.

She still needs a new hip to replace the one sickle cell disease damaged through necrosis. But life already is so much better.

I havent had any infections, I havent had to go to the hospital, I havent had any pain crises or anything, she said. I am so appreciative and grateful for this. It is such a blessing.

Someday, Ramirez hopes to meet and thank her donor.

Her mother would love that, too.

She (the donor) does not realize how much of a life-saver she is and how much she has altered the quality of life for my daughter and even for myself. . We truly appreciate her.

___

Information from: The Kansas City Star, http://www.kcstar.com

More:
First adult cured of sickle cell at a Kansas hospital - Washington Times